Investment Thesis
Invivyd is a pre-commercial or early-stage biopharmaceutical company with severe profitability challenges, burning $58.1M in operating cash flow annually despite 110.5% revenue growth. While the company maintains strong liquidity with $226.7M in cash and minimal debt, the current burn rate combined with negative 98.2% net margins and -109.1% free cash flow margin indicates the business model is not yet viable at scale.
Strengths
- Strong revenue growth of 110.5% YoY indicates market traction and demand
- Excellent liquidity position with $226.7M cash and 7.24x current ratio provides runway for operations
- Negligible debt burden (0.00x debt-to-equity) provides financial flexibility without leverage risk
Risks
- Massive cash burn of $58.1M annually in operating activities threatens sustainability despite large cash reserves
- Severely negative profitability metrics (net margin -98.2%, operating margin -104%) indicate business is unprofitable at scale
- At current burn rate, cash runway appears limited to approximately 3.9 years, requiring path to profitability within that window
- 10 Form 4 insider filings in 90 days may signal insider concerns or management transitions
Key Metrics to Watch
- Operating cash burn rate - critical to track if burn is decelerating with growing revenue
- Gross margin achievement - need visibility on gross profitability to assess unit economics
- Revenue growth sustainability - monitor if 110% growth can be maintained and convert to profitability
- Cash burn runway and path to breakeven - essential for assessing going concern risks
Financial Metrics
Revenue
53.4M
Net Income
-52.5M
EPS (Diluted)
$-0.30
Free Cash Flow
-58.3M
Total Assets
276.9M
Cash
226.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-104.0%
Net Margin
-98.2%
ROE
-21.7%
ROA
-19.0%
FCF Margin
-109.1%
Balance Sheet & Liquidity
Current Ratio
7.24x
Quick Ratio
7.11x
Debt/Equity
0.00x
Debt/Assets
12.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-29T16:04:13.470207 |
Data as of: 2025-12-31 |
Powered by Claude AI